Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Shanghai Pharmaceutical Kangli (Changzhou) Pharmaceutical, received approval from China's National Medical Products Administration from the marketing of the active pharmaceutical ingredient isaconazole sulfate, according to a Shanghai bourse filing on Wednesday.
The drug is an azole antifungal agent, the pharmaceutical company said.